Compare CSX Corporation (CSX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? CSX Corporation trades at $50.1 (market cap $92.55B), while State Street SPDR S&P Biotech ETF trades at $159.16. The key difference: CSX Corporation pays a 1.12% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| CSX | XBI | |
|---|---|---|
Market Cap | $92.55B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $53.21 | $164.28 |
52-Week Low | $32.05 | $86.92 |
Enterprise Value | $110.52B | — |
Dividend Yield | 1.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.08, down slightly by 0.09% today, with a neutral technical signal despite bullish moving averages. The railroad operator posted strong Q2 2026 results with EPS of $0.54 beating estimates by 4.2% and revenue growth of 10%, driving improved investor sentiment. Valuation metrics show a P/E of 29.05 and P/S of 6.41, while profitability remains solid with 22.21% net margins and 24.37% ROE. Recent news highlights volume growth and margin expansion as key catalysts.
CSX demonstrates operational strength with consecutive earnings beats and raised 2026 guidance, supported by intermodal demand and cost controls. However, declining revenue trends from $14.9B in 2022 to $14.1B in 2025 and high debt levels pose risks. Analyst consensus is bullish with a $52.57 price target (4.9% upside), though competitive pressures and fuel costs require monitoring for sustained growth.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
